First human test for new pneumonia shot shows promise
NCT ID NCT05815264
Summary
This early-stage study tested the safety and initial immune response of a new 23-valent pneumococcal vaccine designed to help prevent pneumonia. It involved 144 healthy volunteers, including children and adults, who received either the test vaccine or a control shot. Researchers closely monitored participants for side effects for six months and checked their blood for antibody levels to see if the vaccine triggered a protective immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Qi County Center for Disease Control and Prevention
Hebi, Henan, China
Conditions
Explore the condition pages connected to this study.